Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Authors:
- Ondrej FialaOndrej Fiala
- Jindrich FinekJFJindrich Finek
- Alexandr PoprachAPAlexandr Poprach
- Bohuslav MelicharBMBohuslav Melichar
- Jindrich KopeckýJKJindrich Kopecký
- Milada ZemanovaMZMilada Zemanova
- Katerina KopeckovaKKKaterina Kopeckova
- Tomas MlcochTMTomas Mlcoch
- Tomas DolezalTDTomas Dolezal
- Lenka CapkovaLCLenka Capkova
- Tomas BuchlerTBTomas Buchler
Open Access
Abstract
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.Keywords
Funding Information
- undefined <span style="color:gray;font-size:10px;">undefined</span> (National Sustainability Program I (NPU I) Nr. LO1503)
- Ministerstvo Školství, Mládeže a Tělovýchovy (LO1503)
- Univerzita Karlova v Praze (Progres Q39)
- European Regional Development Fund (CZ.02.1.01/0.0/0.0/17_048/0007280)
- Ministerstvo Zdravotnictví Ceské Republiky (NV19-08-00250)
- Horizon 2020 Framework Programme (Nº856620)
This publication has 32 references indexed in Scilit:
- The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal NeoplasiaAmerican Journal of Surgical Pathology, 2013
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registryAnnals of Oncology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors modelBMC Cancer, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000